60 related articles for article (PubMed ID: 25434358)
1. Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors.
La Regina G; Bai R; Rensen WM; Di Cesare E; Coluccia A; Piscitelli F; Famiglini V; Reggio A; Nalli M; Pelliccia S; Da Pozzo E; Costa B; Granata I; Porta A; Maresca B; Soriani A; Iannitto ML; Santoni A; Li J; Miranda Cona M; Chen F; Ni Y; Brancale A; Dondio G; Vultaggio S; Varasi M; Mercurio C; Martini C; Hamel E; Lavia P; Novellino E; Silvestri R
J Med Chem; 2013 Jan; 56(1):123-49. PubMed ID: 23214452
[TBL] [Abstract][Full Text] [Related]
2. Fragment based group QSAR and molecular dynamics mechanistic studies on arylthioindole derivatives targeting the α-β interfacial site of human tubulin.
Tyagi C; Gupta A; Goyal S; Dhanjal J; Grover A
BMC Genomics; 2014; 15 Suppl 9(Suppl 9):S3. PubMed ID: 25521775
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives.
Tseng CY; Mane JY; Winter P; Johnson L; Huzil T; Izbicka E; Luduena RF; Tuszynski JA
Mol Cancer; 2010 May; 9():131. PubMed ID: 20509970
[TBL] [Abstract][Full Text] [Related]
4. Molecular Dynamics and Machine Learning reveal distinguishing mechanisms of Competitive Ligands to perturb α,β-Tubulin.
Basu D; Dastidar SG
Comput Biol Chem; 2024 Feb; 108():108004. PubMed ID: 38157659
[TBL] [Abstract][Full Text] [Related]
5. Key analogs of a uniquely potent synthetic vinblastine that contain modifications of the C20' ethyl substituent.
Allemann O; Cross RM; Brütsch MM; Radakovic A; Boger DL
Bioorg Med Chem Lett; 2017 Jul; 27(14):3055-3059. PubMed ID: 28551101
[TBL] [Abstract][Full Text] [Related]
6. Indole derivatives as tubulin polymerization inhibitors for the development of promising anticancer agents.
Hong Y; Zhu YY; He Q; Gu SX
Bioorg Med Chem; 2022 Feb; 55():116597. PubMed ID: 34995858
[TBL] [Abstract][Full Text] [Related]
7. Frentizole, a Nontoxic Immunosuppressive Drug, and Its Analogs Display Antitumor Activity via Tubulin Inhibition.
Ramos S; Vicente-Blázquez A; López-Rubio M; Gallego-Yerga L; Álvarez R; Peláez R
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139302
[TBL] [Abstract][Full Text] [Related]
8. Novel Tetrazole Derivatives Targeting Tubulin Endowed with Antiproliferative Activity against Glioblastoma Cells.
Gallego-Yerga L; Chiliquinga AJ; Peláez R
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446273
[TBL] [Abstract][Full Text] [Related]
9. Potent and Selective Benzothiazole-Based Antimitotics with Improved Water Solubility: Design, Synthesis, and Evaluation as Novel Anticancer Agents.
Gallego-Yerga L; Ceña V; Peláez R
Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376146
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Biological Evaluation of Highly Active 7-Anilino Triazolopyrimidines as Potent Antimicrotubule Agents.
Oliva P; Romagnoli R; Cacciari B; Manfredini S; Padroni C; Brancale A; Ferla S; Hamel E; Corallo D; Aveic S; Milan N; Mariotto E; Viola G; Bortolozzi R
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745764
[TBL] [Abstract][Full Text] [Related]
11. Application of ensemble pharmacophore-based virtual screening to the discovery of novel antimitotic tubulin inhibitors.
Gallego-Yerga L; Ochoa R; Lans I; Peña-Varas C; Alegría-Arcos M; Cossio P; Ramírez D; Peláez R
Comput Struct Biotechnol J; 2021; 19():4360-4372. PubMed ID: 34429853
[TBL] [Abstract][Full Text] [Related]
12. Methoxy and bromo scans on
González M; Ovejero-Sánchez M; Vicente-Blázquez A; Medarde M; González-Sarmiento R; Peláez R
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1029-1047. PubMed ID: 34107837
[TBL] [Abstract][Full Text] [Related]
13. Microtubule Destabilizing Sulfonamides as an Alternative to Taxane-Based Chemotherapy.
González M; Ovejero-Sánchez M; Vicente-Blázquez A; Álvarez R; Herrero AB; Medarde M; González-Sarmiento R; Peláez R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673002
[TBL] [Abstract][Full Text] [Related]
14. The Masked Polar Group Incorporation (MPGI) Strategy in Drug Design: Effects of Nitrogen Substitutions on Combretastatin and Isocombretastatin Tubulin Inhibitors.
González M; Ellahioui Y; Álvarez R; Gallego-Yerga L; Caballero E; Vicente-Blázquez A; Ramudo L; Marín M; Sanz C; Medarde M; Pelaéz R
Molecules; 2019 Nov; 24(23):. PubMed ID: 31779228
[TBL] [Abstract][Full Text] [Related]
15. High-affinity ligands of the colchicine domain in tubulin based on a structure-guided design.
Bueno O; Estévez Gallego J; Martins S; Prota AE; Gago F; Gómez-SanJuan A; Camarasa MJ; Barasoain I; Steinmetz MO; Díaz JF; Pérez-Pérez MJ; Liekens S; Priego EM
Sci Rep; 2018 Mar; 8(1):4242. PubMed ID: 29523799
[TBL] [Abstract][Full Text] [Related]
16. New ligands of the tubulin colchicine site based on X-ray structures.
Álvarez R; Medarde M; Peláez R
Curr Top Med Chem; 2014; 14(20):2231-52. PubMed ID: 25434358
[TBL] [Abstract][Full Text] [Related]
17. QSAR and 3D-QSAR models in the field of tubulin inhibitors as anticancer agents.
Marzaro G; Chilin A
Curr Top Med Chem; 2014; 14(20):2253-62. PubMed ID: 25434357
[TBL] [Abstract][Full Text] [Related]
18. Structural insights into the design of indole derivatives as tubulin polymerization inhibitors.
Li Y; Yang J; Niu L; Hu D; Li H; Chen L; Yu Y; Chen Q
FEBS Lett; 2020 Jan; 594(1):199-204. PubMed ID: 31369682
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
